Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEA-BCMA in Relapsed/Refractory Multiple Myeloma
NCT03582033Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Nov 2018
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SEA-BCMA in multiple myeloma (MM) (3 arms), sponsored by Seagen Inc. Primary endpoints: Treatment Emergent Adverse Events up to 45 months, Maximum Laboratory Toxicity Grade up to 45 months and 1 more. Started Nov 2018; status: terminated.
02
Drugs
SEA-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03582033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582033.